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Abstract  
Nanoscale cerium dioxide (nanoceria) has industrial applications, capitalizing on its catalytic, 
abrasive, and energy storage properties. It auto-catalytically cycles between Ce3+ and Ce4+, 
giving it pro-and anti-oxidative properties. The latter mediates beneficial effects in models of 
diseases that have oxidative stress/inflammation components. Engineered nanoparticles 
become coated after body fluid exposure, creating a corona, which can greatly influence their 
fate and effects. Very little has been reported about nanoceria surface changes and biological 
effects after pulmonary or gastrointestinal fluid exposure. The study objective was to address 
the hypothesis that simulated biological fluid (SBF) exposure changes nanoceria’s surface 
properties and biological activity. This was investigated by measuring the physicochemical 
properties of nanoceria with a citric acid coating (size; morphology; crystal structure; surface 
elemental composition, charge, and functional groups; and weight) before and after exposure to 
simulated lung, gastric, and intestinal fluids. SBF-exposed nanoceria biological effect was 
assessed as A549 or Caco-2 cell resazurin metabolism and mitochondrial oxygen consumption 
rate. SBF exposure resulted in loss or overcoating of nanoceria’s surface citrate, greater 
nanoceria agglomeration, deposition of some SBF components on nanoceria’s surface, and 
small changes in its zeta potential. The engineered nanoceria and SBF-exposed nanoceria 
produced no statistically significant changes in cell viability or cellular oxygen consumption 
rates.  
 
Keywords: A549 Cells; body fluids; Caco-2 cells; cellular respiration; cerium; engineered 
nanoparticles; hydrodynamic diameter; microscopy, electron, transmission; nanoceria; 
nanoparticle corona; spectroscopy, Fourier transform infrared; thermogravimetric analysis; X-ray 
diffraction 
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Abbreviations:  
DLS: Dynamic light scattering 
EDS: Energy-dispersive X-ray spectroscopy 
ENP: Engineered nanoparticle 
FaSSGF: Fasted-state simulated gastric fluid 
FeSSGF: Fed-state simulated gastric fluid 
FaSSIF: Fasted-state simulated intestinal fluid 
FeSSIF: Fed-state simulated intestinal fluid 
FTIR: Fourier-transform infrared spectroscopy 
GIF: Gastrointestinal fluid 
OCR: Oxygen consumption rate 
SBF: Simulated body fluid (an inclusive term for FaSSGF, FeSSGF, FaSSIF, FeSSIF, and SLF) 
SLF: Simulated lung fluid 
TEM: Transmission electron microscopy 
TGA: Thermogravimetric analysis 
XRD: Powder X-ray diffraction 
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Introduction 
Engineered nanoparticles (ENPs) are typically coated to enhance their stability (deter 
agglomeration) and/or target their distribution. Once they enter the biological milieu, the coating 
may be removed, altered by body fluids, or overcoated by body fluid components, creating a 
corona. The chemistry and morphology of the nanoparticle surface, what cells “see”, can greatly 
influence its fate and effects [1, 2]. For many nanoparticles the influence of biological fluids to 
remove, alter, or overcoat the applied coatings has not been well characterized. 
 
Studies of Ag nanoparticles exposed to oral and gastrointestinal fluids (GIFs) have been 
reported [3-6]. Reports have described the effect of GIFs on SiO2 and ZnO nanoparticles and 
resultant particle effects on Caco-2 cells [7-9] and the effect of GIFs on CuO nanoparticles and 
small intestine cell response [10]. GIF exposure caused agglomeration/deagglomeration of Ag, 
SiO2, Al0, and γ-Al2O3 nanoparticles [3-5, 8, 11]. With the exception of changes in the zeta 
potential [10] or surface elemental analysis [11] that were not assessed for biological effect, 
nanoparticle surface properties were not reported in these studies.  
 
Exposure of ENPs to GIFs or their components can change their surface properties. The 
surface charge of nanotitania and nanosilica became more electronegative after pancreatin and 
bile extract exposure [12]. Fourier-transform infrared spectroscopy (FTIR) revealed protein and 
bile salt adsorption on nanotitania and nanosilica surfaces. Nanotitania cell toxicity was 
attributed to the bile salt adsorption. Incubation of Fe3O4 nanoparticles with bread in simulated 
salivary and GIFs resulted in size, surface charge, and protein corona changes, resulting in 
morphological changes (an increase in the number of apical membrane vesicles) and greater 
Caco-2 uptake of exposed NPs [13]. Exposure of CdSecore/ZnSshell quantum dots to GIFs altered 
the polyethylene glycol coating, revealed by FTIR. The effect on biological response was not 
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reported [14]. Silicon carbide and TiC nanoparticle exposure to human reconstituted gastric fluid 
resulted in surface carbon and nitrogen adsorption [15]. The surface and pore structure of 
mesoporous SiO2 particles was altered by exposure to salivary and GIF. The effect on biological 
response was not reported [16].  
 
Much less work has been reported with simulated lung fluids (SLFs). Nanoscale ZnO, CuO, 
Fe3O4, TiO2, and CeO2 aggregated in SLFs, including pulmonary artificial lysosomal fluid and 
Gamble solution. Nanoscale CeO2 dissolution was 5.5% after two h in a gastric fluid, < 0.2% 
after two h in an in vitro gastric and four h in an in vitro intestinal fluid, and none after 24 h in 
artificial lysosomal fluid or Gamble’s solution [17]. Exposure of nanoscale CeO2, silica-coated 
CeO2, BaSO4, and ZnO to rat concentrated bronchoalveolar lavage fluid resulted in 
agglomerated particles with increased conductance, a negative surface charge (-19 to -15 mV in 
water), and a corona containing nine identified proteins [18]. The effect on biological response 
of body-fluid exposed NPs in these two studies was not reported.  
 
Nanoceria (nanoscale cerium dioxide, ceria, CeO2) is auto-catalytically redox active, cycling 
between Ce3+ and Ce4+. It has a high oxygen storage capacity. Oxygen vacancies in its cubic 
fluorite structure allow it to easily accept and donate oxygen without significantly altering its 
geometry. These properties are described in detail in [19]. It displays superoxide dismutase and 
catalase mimetic activity. It has commercial applications and therapeutic potential for conditions 
with an oxidative stress/inflammation component [20]. Nanoceria has been shown to have 
beneficial effects in animal models of cardiomyopathy [21], ventricular hypertrophy [22], cardiac 
toxicity [23], ovarian cancer [24], pancreatic cancer [25], ischemic stroke [26], retinal 
degeneration [27], sepsis [28], and hypobaric hypoxia [29]. It has been shown to promote 
wound healing [30] and improve microvascular function in a model of hypertension [31]. Studies 
6 
 
 
 
have shown that it can improve the reproductive system of aged and diabetic male rats [32, 33] 
and provide protection against radiation-induced gastric, lung, salivary, dermatologic, and bone 
marrow toxicity [34-37], and endometriosis [38]. It has been shown beneficial in rodent models 
of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, 
diabetic neuropathy, traumatic brain injury, and intracerebral hemorrhage [39-46]. It has been 
shown to reduce adverse brain effects of diesel exhaust exposure [47], ethanol- and stress-
induced gastric lesions [48, 49], chemical-induced hepatic and pancreatic toxicity [50, 51], and 
ischemia-induced hepatic reperfusion injury [52]. It reduced weight gain [53] and obesity-related 
inflammatory effects [54]. However, there is concern about potential adverse effects from 
nanoceria environmental exposure (e.g., from its use as a diesel fuel additive [55]) and 
occupational exposure [56]. Adverse effects from in vivo pulmonary exposure have been 
demonstrated [57-61].  
 
Cell response to ENPs is dependent on particle physicochemical properties such as size, 
surface charge, and morphology. Consequently, alterations in these characteristics can lead to 
favorable or adverse outcomes. For example, application of a surface coating, such as citrate, is 
routinely conducted to provide biocompatibility and deter agglomeration by providing a charged 
surface [62, 63]. Proteins can coat ENPs to form a corona [1] and be subsequently displaced by 
other proteins or removed. For example, nanoceria reversibly adsorbs albumin. Albumin 
interacts with nanoceria in blood due to its prevalence but would be replaced over time by 
fibrinogen that has a higher affinity [64, 65]. These alterations can change the particle surface 
charge [66]. Aside from two studies ([17] and [18]) we are not aware of reports of the effect of 
lung or GIFs on nanoceria. As noted, in vivo interactions and resulting protein corona formation 
are not well understood and will be a focus in advancing our knowledge of nanoceria’s potential 
biomedical applications [20].  
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This study investigated the effects of human SLF and GIFs on nanoceria surface properties and 
the effect of the simulated body fluid (SBF)-exposed nanoceria on cell viability and oxygen 
consumption, to test the hypothesis that exposure to SBFs results in surface changes that affect 
cell response. It was anticipated that exposure to these SBFs would change the surface charge 
and coating of citrate-coated nanoceria, which might change cell response to the altered 
nanoceria. Nanoceria was synthesized by a hydrothermal method, citrate coated, purified by 
centrifugation and dialysis against water, and extensively characterized to determine its 
physicochemical identity. It was exposed to simulated lung, gastric, and intestinal fluids, and 
then again extensively characterized. The SBF-exposed nanoceria was isolated and its effect 
on the viability and oxygen consumption rate of relevant cells assessed (A549 for SLF-exposed 
nanoceria and Caco-2 for simulated gastric- and intestinal fluid-exposed nanoceria) to 
determine its biological identity.    
 
Materials and Methods 
Materials 
The chemicals, their sources, and purity were: acetic acid (glacial), Fisher Scientific, 100%; 
calcium chloride dihydrate, Fisher Scientific, USP/FCC; cerium nitrate hexahydrate, Fluka 
Analytical, ≥ 99%; citric acid monohydrate, Fisher Chemical, 100%; citric acid trisodium salt 
dihydrate, VWR, ≥ 99%; disodium hydrogen phosphate, Fisher Scientific, ACS grade; lecithin 
from egg, MP Biomedicals, ≥ 96%; hydrochloric acid, Fisher Reagent, 37% ACS grade; 
lipopolysaccharide E. Coli 0127:B8 (LPS), Sigma, ≥ 500,000 EU/mg; magnesium chloride, 
Strem Chemicals, 97.5%; maleic acid, TCI, 99%; pepsin, MP Biomedicals; potassium chloride, 
Sigma, ~ 99%; resazurin, sodium salt, Sigma, ~ 80% dye content; sodium acetate, Sigma 
Aldrich, ≥ 99%; sodium chloride, Sigma, ≥ 99%; sodium hydrogen carbonate, EM, 98.8%; 
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sodium hydroxide, Fisher Chemical, 98.8%; sodium oleate, TCI, > 97%; sodium sulfate, Sigma 
Aldrich, ≥ 99%; sodium taurocholate hydrate, Alfa Aesar, 96%; and Triton-X 100 (Biorad). 
Oligomycin, (4 (trifluoromethoxy) phenyl) carbonohydrazonoyl dicyanide (FCCP) and rotenone 
were obtained from Biomol. Antimycin A was obtained from Sigma.  Regenerated cellulose 
dialysis tubing that allows up to 12,000 to 14,000 MW passage was from Ward's Science, West 
Henrietta, NY. Two % cow milk was used. A549 cells were obtained from Dr. Jill Kolesar, 
College of Pharmacy, University of Kentucky. Caco-2 cells were obtained from Dr. Kyungbo 
Kim, College of Pharmacy, University of Kentucky. The identity of both cell lines was verified by 
the University of Arizona Genetics Core. MEM and DMEM (Gibco), phosphate-free DMEM 
(Gibco), and low endotoxin FBS (Gibco) were used.  
 
Methods 
Nanoceria synthesis 
Nanoceria was synthesized following a hydrothermal method [67]. The goal was to synthesize 
particles that were large enough to isolate and purify by centrifugation and washing. An 
aqueous solution containing 35 mL of 6 M sodium hydroxide and 5 mL of 0.05 M cerium nitrate 
hexahydrate was combined and stirred for 30 min at 350 rpm. The contents were then 
transferred to an autoclave and heated for 24 h at 180 °C, followed by cooling at room 
temperature for 24 h. The resulting suspension containing cerium oxide and sodium nitrate was 
centrifuged at 4200 rpm for 15 min, then washed and repeated three times. The cerium oxide 
pellet was dispersed and dialyzed against 10 volumes (relative to the nanoceria dispersion) of 
deionized water for 72 h at 350 rpm (changed every 24 h) to remove excess salt and cerium 
ions. The nanoceria suspension was centrifuged at 4200 rpm for 15 min, washed and repeated 
three times, and then dried overnight at 80 °C.  
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Citrate layer application 
Approximately 0.3 g of nanoceria was added to a beaker containing 200 mL of 0.05 M citric acid 
adjusted to pH 4.5, stirred for 24 h, then centrifuged at 4200 rpm for 15 min. The supernatant 
was decanted, the citrate-coated particles washed with deionized water three times, then dried 
at 80 °C overnight. The citrate-coated nanoceria was characterized as described below.   
 
Characterization of non-coated, citrate-coated, and SBF-exposed nanoceria 
Powder X-ray diffraction (XRD; Bruker D8 Advance A25 with Cu source) was performed on a 10 
mg sample to determine its crystal structure. The crystal planes of the peaks were assigned as 
described [68]. Selected area electron diffraction was also conducted. Nanoceria was coated on 
copper grids (300 mesh, lacey carbon #01895, from Ted Pella, Redding, CA) by brief immersion 
in the nanoceria dispersion to determine primary particle morphology, size, and surface 
elemental composition. This was conducted by transmission electron microscopy (TEM) and 
scanning transmission electron microscopy (STEM) using a Thermo Scientific Talos F200X 
operated at 200keV and equipped with a 4 silicon drift detector (SDD)-based energy dispersive 
x-ray spectroscopy (EDS) system for chemical composition analysis and surface elemental 
distribution mapping. The TEM images are recorded on a Ceta CCD camera. The polygon tool 
of ImageJ was used to outline 231 particles from five TEM images of citrate-coated nanoceria. 
Geometric comparison of the square root of area vs. Feret diameter demonstrated that the 
particles were near cubic. To determine hydrodynamic diameter by dynamic light scattering 
(DLS) and surface charge as zeta potential, one mg of the dried solid was dispersed in 2 mL of 
deionized water, facilitated by bath sonication for five min, in a cuvette. A 90Plus Nanoparticle 
Size Distribution Analyzer (Brookhaven Instruments Corporation, Holtsville, NY) and LitesizerTM 
500 Particle Analyzer (Anton Paar, Ashland, VA), respectively, were used. Hydrodynamic 
diameter was determined from five consecutive five-minute determinations. The zeta potential 
10 
 
 
 
was determined multiple times from pH 1 to 12. Fourier transform infrared spectroscopy (FTIR) 
was conducted on the dried nanoceria (Nicolet 6700) to identify surface functional groups by 
their vibration-induced peaks in the infrared spectrum. Three scans were obtained for each 
material. FTIR peak assignments were: –C-H, -CH2, and –CH3 1000 to 1500; C-O- ~ 1100; –C-
H 1350 to 1480; -COOH ~ 1380 and 1540; - N-O ~ 1650; C=O 1670 to 1820; and -OH between 
3000 and 3600 cm-1. Thermogravimetric analysis (TGA; Perkin Elmer TGA7) was performed on 
10 to 15 mg samples to determine the extent of citrate and SBF-deposited surface coatings. 
Nitrogen was used as an inert gas purge. The temperature was held at 125 ˚C for 30 minutes to 
release adsorbed water, then raised 10 ˚C/min above 125 ˚C. Increasing the temperature 
causes neighboring surface hydroxyls to lose water and pyrolyzes organic compounds from the 
nanoceria surfaces. 
 
SBF preparation  
Five SBFs; lung fluid (Gamble’s solution, which represents the interstitial fluid deep within the 
lung, as the SLF), fasted-state simulated gastric fluid (FaSSGF), fed-state simulated middle 
gastric fluid (FeSSGF), fasted-state simulated intestinal fluid (FaSSIF), and fed-state simulated 
middle intestinal fluid (FeSSIF) were prepared as described, with modifications [69-71]. 
Preparation of the FeSSIF deviated from the [69] formula by exclusion of glyceryl monocholate 
and from the [71] formula by exclusion of glyceryl monooleate because they prevented isolation 
of washed, dried nanoceria amenable to the characterization described above. The glyceryl salt 
and sodium oleate were excluded from the Caco-2 cell FeSSIF medium because their inclusion 
killed the cells. The SBFs were sterilized by 0.2 µm filtration.  
 
SBF nanoceria exposure 
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Nanoceria (70 mg) and SBF (15 ml) in a 25 ml centrifuge tube were agitated on an orbital 
shaker (INNOVA 4000, New Brunswick Scientific, Edison, NJ) at 250 rpm and 37 °C. Exposure 
to SLF was three h, gastric fluids two h, and intestinal fluids six h, each conducted in three 
independent replications. After exposure, the dispersions were centrifuged at 3500 rpm for 10 
min, washed with deionized water three times, dried overnight at 80 °C, and characterized as 
described above.  
 
Assessment of nanoceria effect on cell metabolism before and after SBF exposure 
To quantify cell metabolism, A549 cells were grown in 24 well plates in DMEM with 10% FBS. 
Caco-2 cells were grown in 24 well plates in Eagle’s MEM with 20% FBS. The resazurin (AKA 
alamarBlue®) assay was used to assess viability of A549 cells to citrate-coated nanoceria that 
had not been SLF exposed as well as SLF-exposed nanoceria, and Caco-2 cells to nanoceria 
before and after simulated gastric and intestinal fluid exposure. The cells were grown to near 
confluence then washed three times (with phosphate-free DMEM) to remove cell culture growth 
medium. They were then exposed to nanoceria (0, 1, 5, 20, and 100 µg/cm2 cell culture dish 
area, equivalent to 0, 3.8, 19, 76, and 380 µg/ml), that had been SBF-exposed, dispersed by 
sonication in the same SBF to maintain the nanoceria surface coating (corona) acquired during 
SBF exposure. Exposure duration was three, two, or six h for lung-, gastric fluid-, and intestinal 
fluid-exposed nanoceria, respectively. They were also exposed to citrate-coated nanoceria that 
had not been SBF exposed, introduced as an iso-osmotic dispersion in citric acid at pH 7.4, 
dispersed in phosphate-free DMEM. The cells were then washed three times (with PBS), 
exposed to 18.75 (for A549 cells) or 25 µg/ml (for Caco-2 cells) resazurin in MEM containing 
10% FBS. Absorbance readings were obtained after one and two h. Addition of 100 µg/ml 
citrate-coated nanoceria to resorufin (the resazurin reduction product) did not alter resorufin 
fluorescence, compared to citric acid addition, suggesting nanoceria does not interfere with the 
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resazurin assay. A549 cells tolerated SLF exposure. Caco-2 cells did not tolerate exposure to 
100% of the simulated gastric or intestinal fluids. It was necessary to include some cell culture 
medium with these four SBFs to avoid very low viability. Gastric and intestinal SBFs were mixed 
with DMEM that was phosphate free (to avoid nanoceria phosphate complexation) and in the 
absence of FBS (to avoid nanoceria protein adherence [72]). Due to the low pH (1.6) of 
FaSSGF we were unable to assess the effect of FaSSGF-exposed nanoceria on Caco-2 cell 
viability in a medium containing mostly FaSSGF. Caco-2 cell viability was < 5% in 100% 
FaSSGF and mixtures containing equal volumes of FaSSGF and cell culture medium compared 
to phosphate- & FBS-free DMEM. Caco-2 cell viability averaged ~ 10 and 95% in the presence 
of 90% FeSSGF:10% phosphate-FBS-free DMEM and 75% FeSSGF:25% phosphate-FBS-free 
DMEM, respectively, compared to phosphate-FBS-free DMEM. Caco-2 cell viability averaged 
109 and 97% in the presence of 90% FaSSIF or FeSSIF, respectively:10% phosphate-FBS-free 
DMEM, compared to phosphate-FBS-free DMEM. Based on these results, during the viability 
assay Caco-2 cells were exposed to 75% of FeSSGF and 25% phosphate- & FBS-free DMEM, 
or 90% of the simulated intestinal fluids and 10% phosphate- & FBS-free DMEM. Viability 
assays were conducted in three independent experiments, each containing two wells with each 
nanoceria concentration. LPS and Triton-X 100 were tested as positive controls. Two-hour 
exposure to 0.1, 0.3, or 1 µg/ml LPS reduced Caco-2 cell viability 3, 13, and 11%, respectively. 
Six-hour exposure to these concentrations reduced Caco-2 cell viability 7, 13, and 13%, 
respectively. We (unpublished results with RAW 264.7 cells) and others have found LPS effects 
to be quite concentration independent [73]. Two-hour exposure to 0.001, 0.003, 0.01, 0.03, 0.1, 
0.3, 1, 3, or 10% Triton-X 100 reduced Caco-2 cell viability to ~ 0 for all but the two lowest 
concentrations (~ 90% viability). After six-hour exposure to 0.001 and 0.003% Triton-X 100, 
Caco-2 cell viability was ~ 80 and 50%, respectively. These results demonstrate resazurin 
assay sensitivity to reduced cell metabolism.  
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Assessment of nanoceria effect on cellular respiration before and after SBF exposure 
Cellular oxygen consumption rates (OCRs) of A549 and Caco-2 cells in response to uncoated, 
citrate-coated, and SBF-exposed citrate-coated nanoceria were determined using a Seahorse 
XFe96 Analyzer (Agilent). The standard Seahorse XF Cell Mito Stress Test protocol was 
performed by measurement of OCRs after stepwise injection of 2.5 µM oligomycin, FCCP (0.5 
µM for A549 cells and 0.25 µM for Caco-2 cells), and 1 µM rotenone and 10 µM Antimycin A 
that generated multiple endpoints of cellular respiration. A549 cells (25,000/well) were exposed 
for three h to DMEM with 10% FBS, phosphate-FBS-free DMEM, uncoated and citrate-coated 
nanoceria in phosphate-FBS-free DMEM, SLF, and nanoceria in SLF that had been immediately 
previously exposed to SLF for three h. Caco-2 cells (20,000/well) were exposed to the same 
conditions for two h with FeSSGF replacing SLF and for six h with FaSSIF and FeSSIF 
replacing SLF. Nanoceria was tested at 0, 1, 5, 20, and 100 µg/cm2 Seahorse plate well area, 
equivalent to 0, 1.1, 5.7, 23, and 114 µg/ml. Each condition was tested in at least duplicate wells 
in at least three replicate experiments. 
 
Data and statistical analysis 
Zeta potential results were fitted using a Carreau equation that models “plateau” areas at high 
and low pH values and a logarithmic region between these two extremes, as we previously 
employed [74].  
 
The uncoated TGA nanoceria data were used as a control for water loss, and additional weight 
losses from the coated samples were attributed to organic acids (acetic, citric, maleic, or 
taurocholic acid) or casein (in the FeSSGF sample). The temperature of comparison was 500 
°C. Material balances were calculated on the organic acid weight losses for an average 
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nanoceria particle size (21.1 nm side length, 9393 nm3 volume). Lost organic coating weights 
were converted to lost volumes using the densities of the specific organic acids, giving an 
estimate of the nanoceria + coating volume and cubic diameter. These were compared to the 
size of an individual organic acid to estimate whether the coating was much less than a 
monolayer, ¼ to ½ a monolayer, a monolayer, or larger. The FeSSGF sample contained milk 
proteins, of which 80% are caseins. Caseins are well-known colloidal particle adsorbents and 
stabilizers [75, 76] and proteins are known to adsorb to nanoceria [74]. Κ-casein, an appropriate 
model for milk proteins, is known to have a typical area of 40 nm2 when adsorbed on colloids 
[75]. The average nanoceria particle had a surface area of 2646 nm2. If Κ-casein coverage was 
a monolayer, the average nanoceria particle of 21.1 nm side length would have 66 Κ-casein 
molecules attached to its surface. The weight of the adsorbed layer was then compared directly 
to the weight of 66 Κ-casein molecules.  
 
Resazurin assay absorbance in the absence of cells was subtracted from the absorbance from 
cell metabolism, expressed as a percentage of the latter, and nanoceria concentration 
dependence, compared to its absence, assessed for statistical significance by one-way ANOVA. 
Cell viability was determined from the one h absorbance results (absorbance was linear from 
zero to one to two h). Results are reported as mean ± S.D. 
 
Oxygen consumption rate results were baselined to non-mitochondrial respiratory rates and 
further normalized to the protein content in the respective well (determined by the BCA method). 
The effect of phosphate-FBS-free DMEM on cell respiration was determined by comparing the 
OCR to it and DMEM with 10% FBS. The effect of SBF on cell respiration was determined by 
comparing cell response to the SBF and phosphate-FBS-free DMEM. The effect of uncoated 
and citrate-coated nanoceria on basal and maximal OCR was determined as the response of 
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cells exposed to nanoceria in phosphate-FBS-free DMEM/cells exposed to phosphate-FBS-free 
DMEM. The effect of SBF exposed-nanoceria on cellular respiration was determined as the 
response to SBF- exposed nanoceria in SBF/the SBF. The mean and standard deviation of the 
experimental averages was calculated and subjected to one-way ANOVA to test for significant 
differences between nanoceria and non-nanoceria-exposed cells. 
 
Results  
Uncoated and citrate-coated nanoceria characterization results 
X-ray diffraction analysis and selected area electron diffraction of the uncoated and citrate-
coated nanoceria demonstrated its crystallinity and showed (111), (200), (220), and (311) 
crystal planes. Figure 1 shows a representative XRD example for citrate-coated nanoceria and 
the predominant crystal planes. Consistent results were obtained with selected area electron 
diffraction (results not shown). The crystalline nature was similar to the reported spectrum for 
cerium oxide (JCPDS Card #34_0394). The crystal structure of nanoceria is cubic fluorite [77]. 
STEM images of the uncoated and citrate-coated nanoceria as well as the nanoceria after SBF 
exposure show it was cubic-shaped (Figure 2). Primary particle size (particles that cannot be 
separated into smaller particles except by the application of ultrahigh energy) determined by 
TEM is shown in Figure 3. Primary particle size distribution was best described as log normal. 
The mean (S.D.) particle size was 21.1 (14.2) nm. Hydrodynamic diameter (the apparent size of 
the solvated/dynamic hydrated particle in an aqueous medium) results determined by DLS, as 
surface area, are displayed in Figure 4, and summarized in Table 1. The hydrodynamic 
diameter of the uncoated and citrate-coated nanoceria was greater than the primary particle 
diameter determined by TEM, suggesting particle agglomeration. Citrate coating produced an ~ 
10 mV greater absolute (negative) surface charge in the circumneutral pH range (Figure 5) and 
a lower (ζinf) pH plateau zeta potential of ~ 30 mV (Table 2). This was associated with an ~ 
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25% reduction of the hydrodynamic diameter, attributed to the greater surface charge-induced 
repulsion of the like-charged nanoceria particles. Successful surface coating with citric acid is 
confirmed by FTIR (Figure 6) that shows an additional peak at (1380 cm-1) attributed to -COO- 
symmetric stretch and the 1% greater weight loss during TGA analysis (Figure 8). This 
translates to on average 0.8 citrate molecules per nm2 on the surface of the primary particle that 
translates to about ½ a monolayer (Table 3). This estimate assumes complete packing of the 
adsorbate molecules on the surface. Random packing of adsorbates on surfaces often covers 
only 50 to 54% of the available area [71].  
 
Effect of simulated body fluid (SBF) exposure on citrate-coated nanoceria and effect of non- and 
SBF-exposed nanoceria on cell viability  
Exposure to SBFs for two to six h produced no observable surface degradation (Figure 2); but 
SBF-dependent effects on hydrodynamic diameter (Figure 4 and Table 1), surface carbon 
(Figure 2), zeta potential (Figure 5 and Table 2), FTIR (Figures 6 and 7), and TGA (Figure 8) 
were seen. Citrate-coated and SBF-exposed nanoceria, up to 100 µg/cm2, did not significantly 
affect A549 or Caco-2 cell viability (Figure 9). Details are described below. 
 
Exposure to SLF resulted in a small increase in the mean hydrodynamic diameter (Figure 4 and 
Table 1), loss of the FTIR peak at ~1380 cm-1 (Figure 6), and less weight loss during TGA 
heating than the citrate-coated nanoceria (Figure 8). These results suggest some removal of 
citrate from the nanoceria surface with possible replacement by a small amount of acetic acid 
resulting in minimal coating thickness (Table 3). This was not accompanied by a less negative 
surface charge (Figure 5) as might be anticipated with less citric acid on the surface, suggesting 
some association of SLF components with the CeO2 surface. A549 cell metabolism was non-
significantly increased by three h exposure to SLF-exposed nanoceria (Figure 9).  
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Nanoceria exposure to FaSSGF increased its mean hydrodynamic diameter ~ 80% (Figure 4 
and Table 1), associated with a less positive zeta potential at the FaSSGF pH (1.6) (Figure 5), 
the loss of the FTIR peak at ~1380 cm-1 that is attributed to citric acid (Figure 6), and less weight 
loss during TGA heating than the citrate-coated nanoceria (Figure 8). The possible loss of 
citrate from the nanoceria surface may be due to FaSSGF’s very low pH (1.6).  
 
Exposure of nanoceria to FeSSGF greatly increased its mean hydrodynamic diameter (Figure 4 
and Table 1). There was no appreciable effect on the zeta potential other than an increase in 
the isoelectric point (IEP) (Figure 5 and Table 2). The reduction of the 1380 cm-1 FTIR peak 
attributed to citrate on the nanoceria surface (Figure 6), appearance of a peak at 1650 cm-1, and 
large weight loss increase during heating (Figure 8) may be due to overcoating by FeSSGF 
component(s), most likely from the milk. There is an additional FTIR peak at ~ 1750 cm-1 
suggesting an organic component of milk was associated with the nanoceria surface. An FTIR 
scan of dried milk is very similar to the FeSSGF-exposed nanoceria scan in the 1300-2000 cm-1 
range, consistent with nanoceria surface coating by milk components (Figure 7). K-casein from 
milk could form a coating that is one (if tightly packed) or two layers (if randomly or loosely 
packed) thick (Table 3). The system containing protein does form a protein ‘corona’ around 
nanoceria. Elemental scan shows FeSSGF-exposed nanoceria had the most carbon on its 
surface among the SBF-exposed nanoceria. The increases in hydrodynamic diameter and IEP 
can be attributed to adsorption of milk components on the nanoceria surface. Caco-2 cell 
viability was not significantly affected by two h exposure to FeSSGF-exposed nanoceria in 75% 
FeSSGF:25% phosphate- & FBS-free DMEM (Figure 9).    
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Exposure of nanoceria to FaSSIF increased its mean hydrodynamic diameter ~ 25% (Figure 4 
and Table 1). The zeta potential at the FaSSIF pH (6.5) became ~ 9 mV more negative (Figure 
5), the 1380 cm-1 FTIR peak was greatly reduced (Figure 6), and weight loss during heating was 
less than seen with citrate-coated nanoceria (Figure 8). The considerable loss of the 1380 cm-1 
FTIR peak attributed to citrate on the nanoceria surface in the absence of increased weight loss 
during heating and lack of additional FTIR peaks suggests removal of most of nanoceria’s 
surface citrate without significant coating by FaSSIF’s organic components (Table 3). FaSSIF-
exposed nanoceria in 90% FaSSIF:10% phosphate-FBS-free DMEM had little effect on Caco-2 
cell viability (Figure 9).  
 
Nanoceria exposure to FeSSIF increased its mean hydrodynamic diameter ~ 155% (Figure 4 
and Table 1). The zeta potential at the FeSSIF pH (5.8) became less negative (Figure 5), the 
1380 cm-1 FTIR peak was greatly reduced in the absence of any new peaks (Figure 6), and 
there was a considerable increase of the weight loss during heating (Figure 8). The loss of the 
1380 cm-1 FTIR peak and increased weight loss during heating suggests overcoating by some 
FeSSIF component(s), perhaps maleic acid, that would produce a monolayer coat on the 
nanoceria (Table 3). The lowest concentration (1 µg/cm2) of FeSSIF-exposed nanoceria in 90% 
FeSSIF:10% phosphate-FBS-free DMEM non-significantly increased Caco-2 cell viability, 
whereas higher concentrations had little effect (Figure 9).  
 
Effect of nanoceria and simulated body fluid (SBF) exposed nanoceria on the oxygen 
consumption rate  
Basal and maximal A549 OCRs in phosphate-FBS-free DMEM were 102 ± 2% (mean ± S.D.) 
and 102 ± 1% of respiration in DMEM with 10% FBS, respectively. Caco-2 basal and maximal 
cell respiration after two h were 85 ± 7% and 95 ± 7%, and after six h 93 ± 3% and 97 ± 3% in 
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phosphate-FBS-free DMEM compared to DMEM with 10% FBS. A549 basal and maximal cell 
respiration in SLF were 91 ± 9% and 93 ± 10% compared to phosphate-FBS-free DMEM. Caco-
2 basal and maximal cell respiration in FeSSGF, FaSSIF, and FeSSIF were 94 ± 25% and 88 ± 
36%, 82 ± 13% and 87 ± 6%, and 84 ± 15% and 67 ± 12% compared to phosphate-FBS-free 
DMEM, respectively.  
Figure 10 shows a representative trace for A549 and Caco-2 results, indicating that the cell 
respiration analyses were performing correctly, and responsive to treatments (oligomycin, 
FCCP, rotenone and antimycin A, and cell culture media). Figure 11 shows the effects of 
uncoated, citrate-coated, and SBF-exposed nanoceria on cellular respiration. There were no 
statistically significant differences between nanoceria treatments and the control (nanoceria 
free) condition. The results suggest nanoceria, uncoated, coated, or SBF-exposed, does not 
have a profound effect on A549 or Caco-2 cell respiration up to 100 µg/cm2 (114 µg/ml), a quite 
high concentration. 
 
 
Discussion:  
To our knowledge this is the first study to investigate the corona formed on nanoceria after 
exposure to GI fluids and the effects of lung and GI fluid corona on cell response.  
 
The lack of change in nanoceria primary particle size or shape during its two to six h SBF 
exposure was expected, given its slow solubility at acidic pH, and lack of significant solubility at 
circumneutral pH [17, 78, 79] and prior studies cited in the introduction to Yokel et al, 2019 [79].  
 
Although there are many reports of nanoceria zeta potential, few provide sufficient details, such 
as pH and medium, to fully interpret the results. Even fewer determined the zeta potential as a 
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function of pH, as conducted in this study.  Two studies reported nanoceria from commercial 
sources to have an IEP of ~ pH 7 in water [80, 81], very different from the IEPs of our citrate-
coated nanoceria. The surface properties of these commercial materials are unknown. We have 
unpublished results that show nanoceria annealed at 300 °C for one h has an IEP of 7.   
 
The increase in nanoceria’s absolute (negative) surface pH after exposure to SLF is probably 
due to association of phosphate with the surface Ce. Cerium is known to form a complex with 
phosphate [82]. Cerium phosphate is quite insoluble, with reported log 
stability/formation/equilibrium constants for Ce3+ phosphate of 3.4 × 1018 [83] and 3.7 × 1023 [84] 
and for Ce4+ phosphate of 2.9 × 1034 [85]. 
 
Some prior studies of A549 viability found no significant effect after four or more h nanoceria 
exposure up to or beyond 100 µg/ml [86-90]. In contrast, a significant decrease after 24 h 
exposure to 3.5 µg/ml nanoceria [91], ~ 90% viability three h after 33 µg/ml [92], 80 and 86% 
viability six and 24 h after exposure to 195 µg/ml [93], 90 and 85% viability after 24 h exposure 
to 100 and 1000 µg/ml [64], and a 10 to 20% viability reduction after 24 h exposure to 67 µg/ml 
[94] were reported. In contrast to a reduction of viability, increased cell viability after 24 h 
exposure to five to 40 µg/ml of 50 and 300 (but not 30) nm ceria was reported [95]. The lack of 
decreased A549 viability in the present study after three h exposure to up to 100 µg/cm2 citrate-
coated nanoceria agrees with most prior reports. Exposure to SLF (Gamble’s solution) did not 
significantly affect nanoceria toxicity. Similar to most studies with A549 cells, prior studies found 
no effect on Caco-2 cell viability after 24 h exposure to up to 200 µg/ml nanoceria [89, 96]. 
Results of the present study with SBF-exposed nanoceria are similar, however they suggest 
that exposure to > 100 µg/cm2 fed-state gastric or intestinal fluid might significantly reduce 
Caco-2 cell viability. In contrast, Caco-2 cell metabolism was reduced when exposed to < 100 
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µg/ml SBF-exposed silver NPs [4], 100 µg/ml FaSSIF-exposed silica NPs [8], < 100 µg/cm2 
SBF-exposed silica or ZnO NPs [9], and 10 µg/ml SBF-exposed nanotitania [12]. Rat IEC-6 cell 
metabolism was reduced when exposed to < 100 µg/ml CuO NPs [10]. 
 
Similar to the cell viability response of A549 and Caco-2 cells to coated and SBF-exposed 
nanoceria, OCR was not significantly affected by uncoated, coated, or SBF-exposed nanoceria. 
There are no prior reports of OCR response to nanoceria. A549 and undifferentiated Caco-2 cell 
OCR were shown to be responsive to nanomaterial and chemical insult [97, 98].    
 
The lack of considerable effect of nanoceria on resazurin metabolism and OCR may be partly 
due to the physical incompatibility of nanoceria in the SBFs. Introduction of the citrate-coated 
nanoceria (as an aqueous dispersion) as well as the nanoceria that had been exposed to SBFs 
(that were dispersed in the SBFs), resulted in visually noticeable nanoceria precipitation on the 
cells. This indicates the lack of stability of nanoceria in the SBFs, which would be expected to 
reduce its potential for cell uptake or cell membrane effects. This may contribute to the low 
biological effects of citrate-coated nanoceria (adverse or beneficial) before and after SBF 
exposure.     
 
Nanoceria has been shown to be taken up by A549 and Caco-2 cells. Nanoceria (9 nm) was 
observed by TEM in A549 cell vesicular structures and cytoplasm within 10 min of exposure. 
Using ICP-MS to study uptake kinetics revealed non-saturated, ~ linear cell association of ~ 
60% of the nanoceria after 30 min [56]. Four h after exposure TEM showed 8 and 20 nm ceria 
close to the A549 cell surface and in aggregates in endocytotic vacuoles. Uptake was 
concentration dependent (from 10, 50, and 200 µg/ml) for 24 h [87]. Confocal microscopy of 
Caco-2 cells showed nanoceria particles in fully differentiated (grown for 14 days) Caco-2 cells 
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after 24 h exposure to 3.125 and 31.25 mg/cm2 < 25 nm ceria [99], and in undifferentiated 
Caco-2 cells, including the nucleus, after 24 h exposure to 100 µg/ml 70 nm ceria [96]. 
 
Nanoceria concentrations in the present study that did not produce significant effects on A549 
cells (≥ 1 µg/cm2) are greater than the nanoceria concentration in ambient air attributed to use 
of nanoceria in diesel fuel (0.5 ng/m3) [100]. The only published study we are aware of that 
assessed occupational nanoceria exposure did not find cerium in air samples during chemical 
mechanical planarization in semiconductor device fabrication [101]. A two-year study of 
nanoceria inhalation (NM212, 40 nm, agglomerates three to 150 µm) was conducted in rats 
exposed to 0.1, 0.3, 1, or 3 mg/m3, 6 h daily, 5 days weekly. This resulted in time- and dose-
dependent increased polymorphonuclear leukocytes in the bronchoalveolar lavage fluid 
(indicating inflammation), granuloma formation and giant cells after 12 months exposure to 1 
mg/m3, and moderate chronic inflammation after 24 month exposure to 3 mg/m3 [102]. An 
aerosol containing 1 mg/m3 nanoceria would contain one µg in 1000 cm3. Rat minute ventilation 
is ~ 30 ml(cm3)/min [103]. One µg/cm2 (the lowest A549 cell exposure of the present study) 
would represent the nanoceria inhaled from 1 mg/m3 by a rat in ~ 0.5 h. The A549 results 
suggest neither the citrate-coated or SLF-exposed nanoceria would be predicted to result in 
adverse effects after acute exposure to the nanoceria concentrations studied in rats or likely to 
be inhaled by humans during occupational exposure.   
 
Conclusion 
Nanoceria synthesis was confirmed by XRD and selected area electron diffraction results 
(crystalline identity) and EDS results (cerium and oxygen). Citrate coating addition was 
demonstrated by a decrease in hydrodynamic diameter, an increase in the absolute surface 
charge, FT-IR appearance of a carboxylate-assignable peak, and a moderate increase in mass 
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loss during TGA heating. Some of the citrate persisted on the nanoceria surface after SBF 
exposure. Following FeSSGF exposure, hydrodynamic diameter and weight loss during heating 
increased, suggesting addition of material to the nanoceria surface. Similar, but less profound, 
changes were seen following FeSSIF exposure. Exposure to SLF, FaSSGF, and FaSSIF 
resulted in subtle changes. Neither the citrate-coated or SBF-exposed nanoceria produced 
significant cell toxicity, suggesting acute nanoceria exposure to concentrations less than 
extraordinary would not be predicted to produce adverse pulmonary or gastrointestinal effects.  
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Table 1. Nanoceria hydrodynamic size. 
Nanoceria 
sample 
Bimodal size distribution  
(% by nm range) 
Uncoated  41% 150-180; 59% 415-540 
Citrate coated 45% 85-105; 59% 310-450 
SLF exposed 43% 135-170; 57% 430-575 
FaSSGF exposed 50% 185-250; 50% 600-775 
FeSSGF exposed 43% 270-445; 57% 2450-3000 
FaSSIF exposed 51% 135-185; 49% 420-550 
FeSSIF exposed 38% 185-285; 62% 870-1150 
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Table 2. Model estimates of the isoelectric point (IEP) and upper (ζ0) and lower (ζinf) pH plateau 
zeta potentials.   
 
  Uncoated Citrate coated 
SLF 
exposed  
FaSSGF 
exposed  
FeSSGF 
exposed 
FaSSIF 
exposed  
FeSSIF 
exposed  
IEP (pH) 2.7 2.7 2.6 2.6 3.5 2.4 2.9 
ζ0 (mV) 19.8 27.5 11.9 11.1 20.4 7.3 8.8 
ζinf (mV) -21.5 -31.1 -35.6 -34.8 -29.0 -39.8 -35.6 
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Table 3. Estimated coating thickness of citrate and simulated body fluids on nanoceria. 
 
Sample Sorbed ligand Diameter of 
sorbed 
complex 
(nm) 
Adsorbate 
molecule 
diameter (nm) 
Coating 
thickness 
Uncoated Control 21.1 Control Control 
FaSSIF exposed a Maleic acid 21.2 0.61 << monolayer 
SLF exposed a Acetic acid 21.2 0.57 << monolayer 
FaSSGF exposed a Taurocholic acid 21.3 1.1 ≈ ¼ monolayer 
Citrate coated a Citric acid 21.4 0.72 ≈ ½ monolayer 
FeSSIF exposed a Maleic acid 21.6 0.61 ≈ 1 monolayer 
FeSSGF exposed b K-casein Not applicable Not applicable 1 to 2 layers 
a estimated from the weight of the coating for the average nanoceria particle diameter. 
b estimated by assuming that Κ-casein adsorbed to the average nanoceria particle size and 
comparing the adsorbed weight to a closely packed (one layer) or randomly packed (two layers) 
structure. 
  
28 
 
 
 
Figures:  
 
Figure 1. X-ray powder diffraction of the as-synthesized citrate-coated nanoceria.  
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Figure 2. STEM images of nanoceria before and after SBF exposure and surface cerium, 
oxygen, and carbon elemental maps. Each of the images in a row are the same size. A 50 nm 
scale bar is in the first column of the row.  
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Figure 3: Primary particle size distribution. Open circles are results of the 231 sized particles. 
Solid line is the log normal distribution model for best fit.  
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Figure 4. Nanoceria hydrodynamic diameter, as surface area, before and after SBF exposure. 
(a) Nanoceria before citrate coating and SBF exposure. (b) Citrate-coated nanoceria before 
SBF exposure. Nanoceria after exposure to (c) SLF, (d) FaSSGF, (e) FeSSGF, (f) FaSSIF, and 
(g) FeSSIF.  
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Figure 5. Nanoceria surface charge (zeta potential) before and after citrate coating, and after 
exposure to each SBF.  
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Figure 6. Fourier transform infrared spectroscopy of the nanoceria before and after citrate 
coating and after exposure to each SBF. Vertical dashed lines indicate –OH at 3400, N-O at 
1650, and –COOH at 1380 cm-1.  
 
  
34 
 
 
 
Figure 7. Fourier transform infrared spectroscopy of dried milk and nanoceria after FeSSGF 
exposure. Vertical dashed lines indicate –OH at 3300, N-O at 1650, and –COOH at 1380 cm-1.  
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Figure 8. Thermogravimetric analysis of nanoceria before and after citrate coating, and after 
exposure to each SBF.  
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Figure 9. Cell viability after exposure to nanoceria that had not or had been SBF exposed. The 
standard deviation of the 100 µg/cm2 results in the lower left panel “Caco-2 cell response to 
FaSSIF-exposed nanoceria” is 0.  
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Figure 10. A549 and Caco-2 cell oxygen consumption rate response to selected media and 
SBF-exposed nanoceria. Upper panel: A549 cell OCR response to selected media and 100 
µg/cm2 SLF-exposed nanoceria. Lower panel: Caco-2 cell OCR response to selected media and 
100 µg/cm2 FeSSIF-exposed nanoceria.  
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Figure 11. A549 and Caco-2 cell basal and maximal oxygen consumption rate responses to 
uncoated, citrate-coated, and SBF-exposed nanoceria.  
  A549 cell response to uncoated, citrate-coated, and SLF-exposed nanoceria 
 
Caco-2 cell two h response to uncoated, citrate-coated, and FeSSGF-exposed                          
nanoceria 
 
         Caco-2 cell six h response to uncoated and citrate-coated nanoceria 
 
 
 
 
       Caco-2 cell six h response to FaSSIF- and FeSSIF-exposed nanoceria 
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